FO
FPRX

FT Options’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

FT Options’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-34,300
Closed -$174K – 422
2016
Q1 		$174K Buy
34,300
+2,000
+6% +$68.7K 0.18% 93
2015
Q4 		$206K Buy
+32,300
New +$1.08M 0.15% 102

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FT Options's FPRX Position: Q2 2016 in Review

FT Options sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2016, closing a stake of 15,312 shares — an estimated $622K sold.

FT Options first reported a position in FPRX in Q4 2015 and held it in 2 quarters. The position peaked at $622K in Q1 2016. 170 funds tracked by Wall St. Rank hold FPRX as of Q2 2016.

  • FT Options reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • FT Options sold 15,312 Five Prime Therapeutics, Inc. shares in Q2 2016, an estimated $622K.
  • FT Options first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
  • FT Options's Five Prime Therapeutics, Inc. position peaked at $622K in Q1 2016.
  • 170 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2016.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.